002550 千红制药
未开盘 04-30 09:30:00
资讯
新帖
简况
股市必读：千红制药（002550）4月29日董秘有最新回复
证券之星 · 04:36
股市必读：千红制药（002550）4月29日董秘有最新回复
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27 19:29
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
千红制药：公司可转债项目尚处于有序推进过程中
证券之星 · 04-27 11:33
千红制药：公司可转债项目尚处于有序推进过程中
股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%
证券之星 · 04-27
股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%
千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%
证券之星 · 04-24
千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%
千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%
智通财经 · 04-23
千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-23
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-20
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-17
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中
证券之星 · 04-14
千红制药：公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
证券之星 · 04-10
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
证券之星 · 04-09
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
千红制药：河南千牧项目已按计划于2025年7月正式投产并稳定运行
证券之星 · 04-01
千红制药：河南千牧项目已按计划于2025年7月正式投产并稳定运行
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
证券之星 · 03-25
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
千红制药：截至当前公司尚未收到方圆制药项目的管辖法院出具的公开裁定文书
证券之星 · 03-24
千红制药：截至当前公司尚未收到方圆制药项目的管辖法院出具的公开裁定文书
股市必读：千红制药（002550）3月23日收盘跌5.67%，主力净流出336.92万元
证券之星 · 03-24
股市必读：千红制药（002550）3月23日收盘跌5.67%，主力净流出336.92万元
千红制药：公司十分重视市值管理工作
证券之星 · 03-16
千红制药：公司十分重视市值管理工作
千红制药：公司自创司之初便坚定实施创新驱动发展战略
证券之星 · 03-12
千红制药：公司自创司之初便坚定实施创新驱动发展战略
股市必读：千红制药（002550）新发布《关于向不特定对象发行可转换公司债券的审核问询函回复及申请文件更新的提示性公告》
证券之星 · 03-12
股市必读：千红制药（002550）新发布《关于向不特定对象发行可转换公司债券的审核问询函回复及申请文件更新的提示性公告》
千红制药（002550）披露向不特定对象发行可转换公司债券募集说明书（修订稿），3月10日股价上涨1.19%
证券之星 · 03-10
千红制药（002550）披露向不特定对象发行可转换公司债券募集说明书（修订稿），3月10日股价上涨1.19%
加载更多
公司概况
公司名称：
常州千红生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-02-18
主营业务：
常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。
发行价格：
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":7.09,"timestamp":1777510977000,"preClose":7.09,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":941000000,"shares":1280000000,"eps":0.2523,"marketStatus":"未开盘","change":0,"latestTime":"04-30 09:30:00","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.2523,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777512600000},"marketStatusCode":0,"adr":0,"adjPreClose":7.09,"symbolType":"stock","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":7.8,"lowLimit":6.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":3.18,"roa":"--","peRate":28.101467,"roe":"3.03%","epsLYR":0.32,"committee":0,"marketValue":9074000000,"turnoverRate":0,"status":2,"floatMarketCap":6673000000},"requestUrl":"/m/hq/s/002550","defaultTab":"news","newsList":[{"id":"2631152151","title":"股市必读：千红制药（002550）4月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2631152151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631152151?lang=zh_cn&edition=full","pubTime":"2026-04-30 04:36","pubTimestamp":1777495010,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，千红制药报收于7.09元，下跌0.28%，换手率1.19%，成交量11.23万手，成交额7985.95万元。董秘最新回复投资者： 从2025年公司的发展治理报告看到公司和天目湖健康研究院、昔关瑞等机构成立联合实验室是不是真的？当日关注点来自交易信息汇总：4月29日主力资金净流出970.83万元，散户资金净流入888.5万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000012882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300723","BK0188","LU2328871848.SGD","BK0028","BK0183","BK0209","LU1969619763.USD","BK0191","BK0175","BK1161","BK1574","BK0132","BK0187","BK0071","BK0196","000950","688117","06978","002550","600216","BK0216","301281","000963","BK0239","688621","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630356449","title":"千红制药：公司可转债项目尚处于有序推进过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2630356449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630356449?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:33","pubTimestamp":1777260819,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药04月27日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司于2024年12月召开2024年第三次临时股东大会审议通过的可转债预案，已于2025年12月召开2025年第二次临时股东会审议通过了修订稿，公司可转债项目尚处于有序推进过程中，后续进展将依法及时公告，感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700017540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336937","title":"股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630336937?lang=zh_cn&edition=full","pubTime":"2026-04-27 03:27","pubTimestamp":1777231631,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告千红制药2025年年报显示，当年度公司主营收入15.71亿元，同比上升2.95%；归母净利润3.99亿元，同比上升12.01%；扣非净利润2.83亿元，同比上升5.33%；其中2025年第四季度，公司单季度主营收入3.56亿元，同比上升11.81%；单季度归母净利润1556.93万元，同比下降66.48%；单季度扣非净利润1229.98万元，同比下降69.83%；负债率10.43%，投资收益1159.24万元，财务费用480.94万元，毛利率58.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127814","title":"千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629127814?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:36","pubTimestamp":1777023368,"startTime":"0","endTime":"0","summary":"证券之星消息，近日千红制药披露，截至2026年3月31日公司股东户数为7.45万户，较12月31日增加1768.0户，增幅为2.43%。在化学制药行业个股中，千红制药股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.51万户。从股价来看，2025年12月31日至2026年3月31日，千红制药区间跌幅为2.8%，在此期间股东户数增加1768.0户，增幅为2.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629557398","title":"千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629557398","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629557398?lang=zh_cn&edition=full","pubTime":"2026-04-23 23:33","pubTimestamp":1776958392,"startTime":"0","endTime":"0","summary":"智通财经APP讯，千红制药(002550.SZ)发布2026年第一季度报告，第一季度，公司实现营业收入3.58亿元，同比下降20.58%。归属于上市公司股东的净利润8505.51万元，同比下降47.16%。归属于上市公司股东的扣除非经常性损益的净利润7740.74万元，同比下降27.60%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629100079","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2629100079","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629100079?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:06","pubTimestamp":1776927979,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘:为什么你在前期回复公司的创新药106项目的临床进度，说法和监管部门窗口实际批准公布临床存前后不一、自相矛盾？是否涉嫌故意误导投资者？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300037287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628717097","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2628717097","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628717097?lang=zh_cn&edition=full","pubTime":"2026-04-20 15:36","pubTimestamp":1776670567,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘:你以前在互动易提问回复中说106创新药正在和CDE沟通申请进行三期临床试验，那么在长达一年的时间里开了几次沟通会议、有没有沟通记录和监管部门给出了什么切实可行建议？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000015018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628226228","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2628226228","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628226228?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:42","pubTimestamp":1776386529,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药04月16日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700009972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627241833","title":"千红制药：公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2627241833","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627241833?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:04","pubTimestamp":1776150256,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：为什么公司的创新药106二期临床补充验证迟迟没有开展？是否属于事实上夭折失败项目？千红制药回复：尊敬的投资者，您好，公司原创一类新药QHRD106项目处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规要求披露。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041400018641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626607981","title":"千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2626607981","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626607981?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:24","pubTimestamp":1775809452,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月10日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的106要进行b的临床，但是董秘却在互动中回复说和监管部门沟通期临床，请问这是不是刻意误导行为？千红制药回复：尊敬的投资者，您好，公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041000027292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","002550","BK0239","06978","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626909694","title":"千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2626909694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626909694?lang=zh_cn&edition=full","pubTime":"2026-04-09 15:03","pubTimestamp":1775718191,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你长期选择性发布公告，公司是不是存在严重的问题？千红制药回复：尊敬的投资者，您好，公司严格按照证监会和交易所的相关规定履行信息披露义务，不存在应披露未披露的重大事项。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040900018613.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624644975","title":"千红制药：河南千牧项目已按计划于2025年7月正式投产并稳定运行","url":"https://stock-news.laohu8.com/highlight/detail?id=2624644975","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624644975?lang=zh_cn&edition=full","pubTime":"2026-04-01 11:34","pubTimestamp":1775014475,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药03月31日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，关注到河南千牧项目粗品线已于2025年6月投产并稳定运行，请问目前原料药车间的建设进度如何？计划是分步进行还是同步推进？千红制药回复：尊敬的投资者，您好，河南千牧项目已按计划于2025年7月正式投产并稳定运行，公司将严格按照GMP标准并遵循相关法规要求有序推进后续工作，力争早日实现产业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040100018459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622026790","title":"千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2622026790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622026790?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:54","pubTimestamp":1774428864,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)03月25日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘公司近期经常隐瞒和延迟发布上市公司的重大消息是否已经严重违反了证监会的规定了？千红制药回复：尊敬的投资者，您好，公司严格按照证监会和交易所的相关规定履行信息披露义务，不存在应披露未披露的重大事项。公司将持续提升规范运作水平和信息披露质量，切实保障全体股东的合法权益。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500031314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621378290","title":"千红制药：截至当前公司尚未收到方圆制药项目的管辖法院出具的公开裁定文书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621378290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621378290?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:33","pubTimestamp":1774323217,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)03月23日在投资者关系平台上答复投资者关心的问题。投资者提问：方圆制药事实上已经到了破产清算状态，这么重大的事项公司都没有及时按照法律法规发布公告，是不是要追究相关人员法律责任并赔偿股票投资者的损失？千红制药回复：尊敬的投资者，您好，截至当前，公司尚未收到方圆制药项目的管辖法院出具的公开裁定文书。公司严格按照相关法律法规履行信息披露义务，不存在应披露未披露的重大事项。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400016093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","01477","BK1191","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621508194","title":"股市必读：千红制药（002550）3月23日收盘跌5.67%，主力净流出336.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621508194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621508194?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:54","pubTimestamp":1774295651,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，千红制药报收于6.82元，下跌5.67%，换手率2.26%，成交量21.31万手，成交额1.48亿元。当日关注点来自交易信息汇总：千红制药股价连续3日下跌，累计跌幅达8.91%，主力资金前10个交易日累计净流出4786.57万元。交易信息汇总股价提醒3月23日千红制药收盘报6.82元，跌5.67%，当日成交2131.16万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619322584","title":"千红制药：公司十分重视市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2619322584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619322584?lang=zh_cn&edition=full","pubTime":"2026-03-16 15:08","pubTimestamp":1773644897,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)03月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问:公司有没有按照证监会规章制定专业性的市值管理制度？千红制药回复：尊敬的投资者，您好，公司十分重视市值管理工作，将始终按照证监会、交易所的相关规则要求做好市值管理的相关工作，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600014287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618413224","title":"千红制药：公司自创司之初便坚定实施创新驱动发展战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2618413224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618413224?lang=zh_cn&edition=full","pubTime":"2026-03-12 20:52","pubTimestamp":1773319933,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药03月11日在投资者关系平台上答复投资者关心的问题。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200036802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618922997","title":"股市必读：千红制药（002550）新发布《关于向不特定对象发行可转换公司债券的审核问询函回复及申请文件更新的提示性公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2618922997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618922997?lang=zh_cn&edition=full","pubTime":"2026-03-12 01:23","pubTimestamp":1773249790,"startTime":"0","endTime":"0","summary":"关于常州千红生化制药股份有限公司向不特定对象发行可转换公司债券并在主板上市之上市保荐书华泰联合证券出具上市保荐书，认为发行人符合上市条件，同意推荐上市。关于向不特定对象发行可转换公司债券的审核问询函回复及申请文件更新的提示性公告公司已于2026年2月12日收到深交所出具的审核问询函，现已会同相关中介机构完成回复，并对申请文件进行补充和修订。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031200000878.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618951184","title":"千红制药（002550）披露向不特定对象发行可转换公司债券募集说明书（修订稿），3月10日股价上涨1.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618951184","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618951184?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:40","pubTimestamp":1773153628,"startTime":"0","endTime":"0","summary":"截至2026年3月10日收盘，千红制药报收于7.63元，较前一交易日上涨1.19%，最新总市值为97.65亿元。该股当日开盘7.57元，最高7.65元，最低7.55元，成交额达8037.39万元，换手率为1.12%。近日，千红制药披露《向不特定对象发行可转换公司债券并在主板上市募集说明书（修订稿）》。公告显示，本次发行可转债总额不超过10亿元，用于创新药研发、湖北钟祥原料药生产基地建设及补充流动资金。本次可转债信用等级为AA，不设担保。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000038620.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777511021904,"stockEarnings":[{"period":"1week","weight":-0.0744},{"period":"1month","weight":-0.0744},{"period":"3month","weight":-0.1138},{"period":"6month","weight":-0.2376},{"period":"1year","weight":0.1858},{"period":"ytd","weight":-0.098}],"compareEarnings":[{"period":"1week","weight":0.0003},{"period":"1month","weight":0.047},{"period":"3month","weight":-0.0121},{"period":"6month","weight":0.0386},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0349}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74524人(较上一季度增加2.43%)","perCapita":"12630股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}